Dr. Shui On LEUNG has nearly 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. Dr. Leung is the first scientist who successfully developed humanised anti-CD22 antibody in the U.S. and the first scientist who introduced the concept of “Functional Humanisation” in the world. Dr. Leung has been a member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited (“HKEx”) since its establishment and an adjunct professor of The Hong Kong University of Science and Technology. He was an executive director of a U.S. leading antibody-drug conjugate company, the managing director of The Hong Kong Institute of Biotechnology Limited, an adjunct professor of Fudan University, China, the Army Medical University (formerly known as the Third Military Medical University), China and the Air Force Medical University (formerly known as the Fourth Military Medical University) and The Chinese University of Hong Kong.

SinoMab BioScience Limited, founded by Dr. Leung, was listed on the main board of the HKEx in November 2019.